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-Secretase (BACE, Asp-2) is a transmembrane aspartic proteinase
responsible for cleaving the amyloid precursor protein (APP) to
generate the soluble ectodomain sAPP and its C-terminal frag-
ment CTF. CTF is subsequently cleaved by -secretase to produce
the neurotoxicsynaptotoxic amyloid- peptide (A) that accumu-
lates in Alzheimer’s disease. Indirect evidence has suggested that
amyloidogenic APP processing may preferentially occur in lipid
rafts. Here, we show that relatively little wild-type BACE is found
in rafts prepared from a human neuroblastoma cell line (SH-SY5Y)
by using Triton X-100 as detergent. To investigate further the
significance of lipid rafts in APP processing, a glycosylphosphati-
dylinositol (GPI) anchor has been added to BACE, replacing the
transmembrane and C-terminal domains. The GPI anchor targets
the enzyme exclusively to lipid raft domains. Expression of GPI-
BACE substantially up-regulates the secretion of both sAPP and
amyloid- peptide over levels observed from cells overexpressing
wild-type BACE. This effect was reversed when the lipid rafts were
disrupted by depleting cellular cholesterol levels. These results
suggest that processing of APP to the amyloid- peptide occurs
predominantly in lipid rafts and that BACE is the rate-limiting
enzyme in this process. The processing of the APP695 isoform by
GPI-BACE was up-regulated 20-fold compared with wild-type
BACE, whereas only a 2-fold increase in the processing of APP751/770
was seen, implying a differential compartmentation of the APP
isoforms. Changes in the local membrane environment during
aging may facilitate the cosegregation of APP and BACE leading to
increased -amyloid production.
A lzheimer’s disease (AD) is characterized pathologically bythe formation of extracellular amyloid plaques in the brains
of patients. These plaques are predominantly composed of the
4-kDa amyloid- (A) peptide, which is derived from the
amyloid precursor protein (APP), a type I transmembrane
protein. APP is cleaved first by -secretase, generating the
soluble ectodomain sAPP, and a membrane-bound C-terminal
fragment (CTF). CTF is subsequently cleaved by -secretase
to release A. -Secretase has been identified as a membrane-
bound aspartic proteinase termed BACE (-site APP-cleaving
enzyme), or Asp-2 (1–3). -Secretase is known to be a multi-
protein complex requiring presenilins for its aspartic proteinase
activity (reviewed in ref. 4). A third APP-cleaving enzyme,
-secretase, cleaves within the A domain releasing the soluble
sAPP domain into the extracellular space and producing CTF,
which is also a -secretase substrate (for review, see ref. 5).
There is increasing evidence from biochemical, epidemiolog-
ical and genetic findings that cholesterol levels are linked to A
production and AD. The 4 allele of apolipoprotein E, which is
associated with higher plasma cholesterol levels, has been shown
to be a risk factor for the disease (6), and levels of serum
low-density lipoprotein and total cholesterol reportedly corre-
late with A levels in the AD brain (7). The prevalence of AD
has been shown by two independent studies to be reduced among
people taking 3-hydroxy-3-methylglutaryl (HMG)-CoA reduc-
tase inhibitors such as lovastatin (8, 9), and this finding is
supported by work on APP-overexpressing mice demonstrating
that increased dietary cholesterol results in higher levels of A
(10). Studies examining the effects of cholesterol loading and
depletion on cells in culture also show a strong link between
cholesterol levels and A production (11, 12); however, the
mechanisms connecting the two are as yet unclear.
A recent hypothesis suggests that lipid rafts could be involved
in APP processing (13). Rafts are areas of the membrane rich in
sphingolipids and acylated proteins, as well as cholesterol.
Certain types of lipid-anchored proteins such as glycosylphos-
phatidylinositol (GPI)-anchored proteins (14), are associated
with these rafts, and rafts have been suggested to be important
in some membrane signaling and trafficking events (15). Bio-
chemically, rafts are characterized by their insolubility in non-
ionic detergents such as Triton X-100 at 4°C (16), and by this
method several proteins relevant to A production have been
shown to be present in raft domains. These proteins include a
small proportion of APP (17, 18), BACE (19), and the prese-
nilins (20), prompting the hypothesis that amyloidogenic pro-
cessing of APP may take place in lipid rafts. The putative
-secretase ADAM10, however, is predominantly soluble after
detergent extraction (21), leading to a model being proposed in
which amyloidogenic and non-amyloidogenic processing of APP
occur in separate membrane compartments (13). According to
this model, a high concentration of membrane cholesterol
therefore favors A production whereas a reduced cholesterol
level favors the non-amyloidogenic -secretase pathway.
To investigate the significance of lipid rafts in APP processing,
we have used the approach of targeting BACE to lipid raft
domains by replacing its transmembrane and cytosolic domains
with a GPI anchor attachment signal. Here we show that
expression of the resulting GPI-anchored form of BACE (GPI-
BACE) in a human neuroblastoma cell line (SH-SY5Y) sub-
stantially up-regulates both the secretion of sAPP into the
medium and the production of A, when compared with the
same cell line expressing wild-type BACE. Disruption of
the rafts by depletion of cholesterol reduced the formation of
sAPP in both GPI-BACE- and wild-type BACE-expressing
cells. Together, these data provide direct evidence for rafts being
the cellular site of A production, and that BACE is the
rate-limiting step in this process.
Experimental Procedures
Generation of GPI-BACE Construct. MycHis-tagged BACE in the
expression vector pcDNA3.1 (1) was stably expressed in SH-
Abbreviations: AD, Alzheimer’s disease; APP, amyloid precursor protein; A, amyloid ;
BACE, -site APP-cleaving enzyme; CTF, C-terminal fragment of APP after  or 
cleavage; GPI, glycosylphosphatidylinositol; KPI, Kunitz protease inhibitor; MCD, methyl-
-cyclodextrin; MBS, MES-buffered saline; PI-PLC, phosphatidylinositol-specific phospho-
lipase C; sAPP,  or  cleaved ectodomain of APP.
‡To whom correspondence should be addressed. E-mail: a.j.turner@leeds.ac.uk.
© 2003 by The National Academy of Sciences of the USA
www.pnas.orgcgidoi10.1073pnas.1635130100 PNAS  September 30, 2003  vol. 100  no. 20  11735–11740
N
EU
RO
SC
IE
N
CE
SY5Y cells. A GPI-anchored form of angiotensin converting
enzyme (22) was provided by R. Skidgel (University of Illinois,
Chicago) and supplied in the expression vector pIRESneo by E.
Parkin (University of Leeds). The angiotensin-converting en-
zyme insert was cleaved from this vector by using EcoRV and
NotI, leaving the pIRESneo vector containing the GPI anchor
signal sequence from human carboxypeptidase M. The pro- and
catalytic domains of BACE were cleaved from pcDNA3.1 by
using EcoRV and BspHI, and then blunt-end ligated into
pIRESneo to produce the GPI-BACE vector.
Cell Culture. SH-SY5Y cells were grown in Dulbecco’s modified
Eagle’s mediumHam’s F-12 (1:1 mix) supplemented with 10%
(volvol) FCS, nonessential amino acids, penicillin (50 units
ml), streptomycin (50 gml), and glutamate (2 mM). Flasks
were incubated at 37°C in 5% CO2. Stable transfections were
carried out by using Lipofectamine Plus (Invitrogen) according
to the manufacturer’s instructions, and transfectants were se-
lected by inclusion of G418 (600 gml) in the medium. For
analysis of secreted proteins, cells were grown to confluency, and
the medium was changed to OptiMEM (GibcoBRL). After
7–24 h of incubation, the medium was harvested and either
assayed for A as described below, or concentrated by centrif-
ugation in a Vivaspin concentrator (molecular weight cutoff
10,000) and analyzed by SDSPAGE and Western blotting. To
analyze cellular proteins, cells were lysed in 50 mM TrisHCl, pH
7.4, containing 1%TritonX-100 and a protease inhibitor mixture
(Roche Diagnostics).
For the cholesterol depletion experiment, cells were treated
with 4 M lovastatin and 200 M mevalonate in OptiMEM for
72 h. Methyl--cyclodextrin (MCD, 5 mM) was then added for
10min. FreshOptiMEM containing 4M lovastatin and 200M
mevalonate was then added to the cells for 3 h before the media
were collected and concentrated as before, and lipid raft frac-
tions were prepared from the cells.
SDSPAGE and Western Blot Analysis. Proteins were resolved by
SDSPAGE by using 10% polyacrylamide gels, and transferred
onto Immobilon P poly(vinylidene dif luoride) membranes.
BACE was detected by using the monoclonal 9B21 antibody
(GlaxoSmithKline, Harlow, U.K.) at 1:1,000 dilution. APP and
fragments were detected by using monoclonal 6E10 antibody
(Signet Laboratories, Dedham, MA) at 1:1,000, polyclonal Ab54
antibody at 1:4,000, monoclonal G26 antibody at 1:1,000 (both
GlaxoSmithKline) or polyclonal anti-Kunitz protease inhibitor
(KPI) antibody (D. Parkinson, Sheffield Hallam University,
Sheffield, U.K.) at 1:500. These four antibodies recognize res-
idues 1–17 of A, the APP C terminus, sAPP, and the KPI
domain of APP, respectively. The antibodies against f lotillin
(BD Biosciences) and -actin (Sigma) were used at 1:250 and
1:5,000, respectively. Horseradish peroxidase-conjugated sec-
ondary antibodies (Jackson Immunoresearch) were used at
1:1,000, and bound antibodies were detected by using the
enhanced chemiluminescence system (Amersham Pharmacia).
Peptide and Protein Assays. The A ELISA was carried out as
described (23). Protein was quantified by using bicinchoninic
acid in a microtiter plate with BSA as standard.
Phospholipase-Mediated Release of GPI-BACE.Phosphatidylinositol-
specific phospholipase C (PI-PLC) purified from Bacillus thu-
ringiensis (24) was diluted in 10 mM HepesNaOH, 150 mM
NaCl, pH 7.4, and filter-sterilized. Confluent cells were rinsed in
OptiMEM and then incubated in OptiMEM containing PI-PLC
at a concentration of 0.17 mgml for 7 h. Media were harvested,
centrifuged at 150,000  g for 30 min, then concentrated and
analyzed by SDSPAGE and immunoblotting.
Neuraminidase and O-Glycosidase Treatment. Confluent cells were
incubated in OptiMEM for 16 h, after which time the medium
was collected and concentrated, and the protein concentration
was equalized. Samples of media were boiled for 5 min in 250
mM sodium acetate, pH 5.5, containing 3% (wtvol) octylglu-
copyranoside, 0.5% (wtvol) SDS, and 5% (volvol) 2-mercap-
toethanol. Neuraminidase (5 milliunits; Sigma) and 1% (wtvol)
Triton X-100 were added, and samples were incubated for 16 h
at 37°C. Following incubation, 1.1 milliunits of O-glycosidase
(Sigma) in 500 mM Tris maleate, pH7.5, containing 0.6%
(wtvol) octylglucopyranoside was added, and samples were
incubated for a further 16 h at 37°C. Equal volumes of treated
and untreated samples were resolved by SDSPAGE.
Lipid Raft Isolation. All steps were carried out at 4°C. Confluent
cells were scraped into 2 ml Mes-buffered saline (MBS, 25 mM
Mes, 0.15MNaCl, pH 6.5) containing 1% (volvol) Triton X-100
and resuspended by passing 5 times through a 25-gauge needle.
An equal volume of 90% (wtvol) sucrose in MBS was then
added. Aliquots (1 ml) were placed in 5-ml ultracentrifuge tubes,
and 4-ml discontinuous sucrose gradients consisting of 35%
(wtvol) sucrose in MBS (2 ml) and 5% (wtvol) sucrose in MBS
(2 ml) were layered on top. The sucrose gradients were centri-
fuged at 100,000  g for 18 h at 4°C in a Beckman SW55 rotor,
and fractions (0.5 ml) were subsequently harvested from the top
to the bottom of the tube.
Results
Expression of WT-BACE and GPI-BACE. Human neuroblastoma SH-
SY5Y cells were stably transfected with cDNA encoding either
WT-BACE or GPI-BACE in which the sequence encoding the
transmembrane and cytosolic domains of BACE had been
replaced with the sequence encoding the GPI anchor attachment
signal of carboxypeptidase M (Fig. 1). Lysates from untrans-
fected SH-SY5Y cells and those transfected with WT-BACE or
GPI-BACE were immunoblotted with a BACE monoclonal
antibody and a polyclonal -actin antibody (Fig. 2). WT-BACE
migrated with a molecular mass of70 kDa whereas GPI-BACE
migrated at a slightly lower molecular weight due to the lack of
the transmembrane and cytosolic domains. The level of expres-
sion of stably transfected WT-BACE was 75% that of GPI-
BACE.
GPI-BACE Can Be Released from Cells by Treatment with PI-PLC. To
confirm that GPI-BACE is attached to the cell membrane via a
GPI anchor, cells stably expressing WT-BACE or GPI-BACE
were treated with exogenous bacterial PI-PLC.Media from these
Fig. 1. Schematic diagram of MycHis-tagged human BACE (WT-BACE) and
the GPI-anchored construct (GPI-BACE). The amino acid sequence of WT-BACE
at the start of the transmembrane domain (bold) is shown. In GPI-BACE, the
transmembrane, cytosolic, and MycHis domains were replaced with the 24-aa
GPI anchor signal sequence (bold, underlined) of human carboxypeptidase M.
The GPI attachment site is marked (*).
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and untreated cells were then analyzed by SDSPAGE and
immunoblotting with an antibody to the catalytic domain of
BACE. In medium from WT-BACE-expressing cells, a low, but
detectable, level of BACE is found both with and without
PI-PLC treatment (Fig. 3). This result agrees with a previous
observation that the ectodomain of the membrane-bound BACE
is shed into the medium to a small extent (25). GPI-BACE also
appears to undergo this shedding event, but to a greater extent
(2.9  0.8-fold increase) than the WT-BACE (Fig. 3). On
PI-PLC treatment of GPI-BACE-expressing cells, a second band
of BACE is detected in the medium at a slightly higher molecular
weight. This predominant form of secreted BACE is likely to be
the product of PI-PLC-mediated cleavage of the GPI anchor
whereas the smaller, less abundant form of soluble BACE results
from protease cleavage in the juxtamembrane region. These
results demonstrate that GPI-BACE is present at the cell surface
where it can be released from the membrane by the action of
PI-PLC and is therefore GPI-anchored.
GPI-BACE Is Localized in Lipid Rafts. BACE can be detected in lipid
rafts, the proportion depending on the particular detergent used
for raft isolation (19). To determine whether GPI-BACE is
raft-localized, cells were solubilized in Triton X-100 and sepa-
rated by buoyant density gradient centrifugation. Gradient frac-
tions were then immunoblotted with a BACE monoclonal an-
tibody and a monoclonal antibody to flotillin, a raft-marker
protein (26) (Fig. 4). All of the flotillin detected from both
WT-BACE- and GPI-BACE-expressing cells was found in the
raft fractions (4–6) as expected. By the Triton solubilization
method used here, the majority of WT-BACE was found in the
soluble, non-raft fractions (7–9), with a small proportion
(10%) present in the raft fractions. GPI-BACE, however, was
located almost exclusively in the raft fractions as expected of a
GPI-anchored protein under these extraction conditions (27).
GPI-BACE Exhibits Increased APP-Cleaving Activity. It has been
proposed that the amyloidogenic processing of APP by BACE
and -secretase may take place in lipid raft domains (13). We
hypothesised that, if this were the case, targeting BACE to lipid
rafts by the addition of a GPI anchor should cause it to colocalize
with the small fraction of APP present in rafts, substantially
increasing its amyloidogenic processing. To investigate this
possibility, SH-SY5Y cells stably expressing WT-BACE or GPI-
BACE, and untransfected cells, were grown for 16 h in serum-
free medium, after which time full-length APP expression and
sAPP and sAPP secretion were evaluated by immunoblotting.
The level of full-length APP was found to be unchanged on
expression of eitherWT- or GPI-BACE (Fig. 5A), indicating that
any changes observed in secreted APP are not due to altered
APP holoprotein expression.
The -secretase cleavage product, sAPP, was detected in
conditioned medium by immunoblotting with the antibody 6E10,
which recognizes residues 1–17 of the A region. This experi-
ment revealed a small decrease (10%) in secretion of sAPP
from cells overexpressing GPI-BACE when compared with
levels seen from untransfected cells or cells expressing WT-
BACE (Fig. 5B).
When media were analyzed by immunoblotting with an anti-
body recognizing the epitope produced by -site cleavage of
APP, the level of sAPP produced by cells expressing WT-
BACEwas seen to be substantially increased (25-fold) over the
low levels observed from untransfected cells (Fig. 5C). In
addition, a second band of sAPP could be seen at a slightly
lower molecular weight. On expression of GPI-BACE, a further
2-fold increase in the upper band of sAPP was seen over the
level secreted fromWT-BACE-expressing cells. The level of the
lower band, however, was increased 20-fold (Fig. 5C).
When the same media samples were immunoblotted with an
antibody recognizing the KPI domain of APP, only the upper
band was detected (Fig. 6A). This finding indicates that the lower
band, which was increased 20-fold on GPI-BACE expression, is
derived from APP695, the shorter, non-KPI-containing isoform.
Treatment of media samples with neuraminidase and O-
glycosidase, to remove O-glycans, shifted both of these bands to
lower molecular weights (Fig. 6B). This result supports the
Fig. 2. Expression of WT-BACE and GPI-BACE in SH-SY5Y cells. SH-SY5Y cells
were stably transfected with either WT-BACE or GPI-BACE as described in
Experimental Procedures. Cell lysates were prepared from transfected (WT or
GPI) and untransfected (Un) cells, and immunoblotted by using the monoclo-
nal 9B21 antibody to BACE or a polyclonal -actin antibody.
Fig. 3. Release of GPI-BACE from cells by exogenous PI-PLC treatment.
Confluent SH-SY5Y cells stably expressing WT-BACE or GPI-BACE were incu-
bated in OptiMEM  PI-PLC for 7 h, after which the medium was collected,
centrifuged at 150,000  g for 30 min, and concentrated. Equal amounts of
protein from media samples were analyzed by SDSPAGE and immunoblotted
with the monoclonal 9B21 antibody to BACE.
Fig. 4. Isolation of lipid rafts from SH-SY5Y cells stably expressing WT-BACE
or GPI-BACE. Lipid rafts were prepared as described in Experimental Proce-
dures from cells stably expressing WT-BACE (A) or GPI-BACE (B). Sucrose
gradients were harvested in 0.5-ml fractions (fraction 1, top of gradient;
fraction 9, bottom of gradient), and each fraction was analyzed by SDSPAGE
and immunoblotted with the monoclonal 9B21 BACE antibody or a monoclo-
nal flotillin antibody.
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hypothesis that the two bands seen in Fig. 5C arise from cleavage
of different isoforms of APP (APP770/751 and APP695) and not
from mature and immature forms of the protein.
To determine whether the increase observed in sAPP pro-
duction by GPI-BACE was linked to an increase in A produc-
tion, levels of secreted A were measured by using a previously
established ELISA (23). A secreted from untransfected cells
and those expressing WT-BACE was below the level of sensi-
tivity of the method. However, GPI-BACE-expressing cells
secreted detectable levels of both A1–40 and A1–42 (Table 1).
Because the assay is sensitive to0.05 ngml A, the level of A
species detected from GPI-BACE-expressing cells represents an
increase in A1–40 of at least 11.6-fold over that seen from
WT-BACE-expressing cells.
Disruption of Raft Domains by Decreasing Cellular Cholesterol Inhibits
APP Cleavage by GPI-BACE. The results described above demon-
strate that targeting BACE to lipid rafts increases -cleavage of
APP. To confirm that the raft-localization of GPI-BACE is
essential for this up-regulation, we disrupted the raft domains by
depleting cells of cholesterol and then compared levels of sAPP
produced with those from untreated cells.
Cholesterol depletion was achieved by treatment of cells with
lovastatin and MCD. In the presence of a small amount of
mevalonate, lovastatin prevents cholesterol synthesis by inhibi-
tion of 3-hydroxy-3-methylglutaryl-CoA reductase whereas
MCD extracts cholesterol from the plasma membrane. Lipid
raft isolation was carried out as described in Experimental
Procedures by using WT- or GPI-BACE-expressing cells incu-
bated for equal lengths of time in the presence or absence of
cholesterol-lowering agents. Fractions were analyzed by SDS
PAGE and immunoblotted for BACE and flotillin (Fig. 7A).
Following treatment of the cells with lovastatin and MCD,
55% of both GPI-BACE and flotillin were found in the
non-raft fractions (7–9).
Media from WT-BACE- or GPI-BACE-expressing cells in-
cubated with or without lovastatin and MCD were collected,
concentrated, and analyzed for sAPP (Fig. 7B). Depletion of
cholesterol and the resulting disruption of lipid raft domains led
to a substantial decrease in sAPP production from both
WT-BACE- and GPI-BACE-expressing cells. Densitometric
Fig. 5. Comparison of APP cleavage by WT-BACE and GPI-BACE. Confluent
untransfected SH-SY5Y cells or cells stably expressing WT-BACE or GPI-BACE
were incubated in OptiMEM for 16 h, after which the medium was collected
and concentrated and cell lysates were prepared. Equal amounts of protein
from media and lysates were analyzed by SDSPAGE and immunoblotting. (A)
Detection of full-length APP and -actin in cell lysates with the polyclonal
Ab54 antibody to APP and a polyclonal -actin antibody. (B) Detection of
sAPP in media by using the monoclonal 6E10 antibody. (C) Detection of
sAPP in media by using antibody G26, which recognizes the epitope of APP
produced by -site cleavage. Densitometric analysis of immunoblots was
carried out, and the mean results  SEM (n  3) are shown graphically.
Fig. 6. Analysis of sAPP isoforms secreted by WT-BACE- and GPI-BACE-
expressing cells. Media were collected from untransfected SH-SY5Y cells or
cells stably expressing WT-BACE or GPI-BACE as described in Fig. 5. (A) Detec-
tion of KPI-containing APP isoforms by using an anti-KPI antibody. (B) Media
samples were treated with neuraminidase and O-glycosidase as described in
Experimental Procedures. Treated and untreated samples were analyzed by
SDSPAGE and immunoblotting with the G26 antibody.
Table 1. Levels of A secretion from SH-SY5Y cells stably
expressing WT-BACE or GPI-BACE
Cell type A1–40, ngml A1–42, ngml n
Untransfected SH-SY5Y 0.05 0.05 3
WT-BACE 0.05 0.05 3
GPI-BACE 0.58  0.03 0.19  0.04 3
Confluent untransfected SH-SY5Y cells or cells stably expressing WT-BACE
or GPI-BACE were incubated in OptiMEM for 16 h. The medium was collected
and analyzed for A1–40 and A1–42 as described in Experimental Procedures.
Results are the mean  SEM (n  3).
Fig. 7. The effect of lovastatin and MCD treatment on APP cleavage by
GPI-BACE. Confluent SH-SY5Y cells stably expressing WT-BACE or GPI-BACE
were treated with lovastatin and methyl--cyclodextrin as described in Exper-
imental Procedures, or incubated in OptiMEM for equal lengths of time. The
medium was collected, and lipid rafts were prepared as described. (A) Sucrose
gradients were harvested in 0.5-ml fractions (fraction 1, top of gradient;
fraction 9, bottom of gradient), and each fraction was analyzed for BACE and
flotillin by SDSPAGE and immunoblotting with the monoclonal 9B21 BACE
antibody or a monoclonal flotillin antibody. (B) Media collected from WT-
BACE- or GPI-BACE-expressing cells incubated in the absence or presence of
lovastatin was concentrated, and equal amounts of protein were analyzed by
SDSPAGE and immunoblotting with the G26 antibody to sAPP. Densitomet-
ric analysis was carried out, and the mean results  SEM (n  3) are shown
graphically (black bars, untreated cells; gray bars, treated cells).
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analysis showed that there was an 7-fold reduction in
sAPP770/751 from both cell types (Fig. 7B) whereas sAPP695
production from GPI-BACE-expressing cells had been com-
pletely eliminated.
Discussion
BACE is the major, and probably only, enzyme in the brain
responsible for cleavage of the amyloid precursor protein at the
-site. Knockout of BACE in mice completely abolishes pro-
duction of A (28, 29), and this result, together with the
observation that these mice are viable, makes BACE an attrac-
tive therapeutic target. However, very little is currently known
about the cellular mechanisms regulating the activity of BACE.
One major factor known to be involved in the regulation of
APP processing is cholesterol. Elevated cholesterol levels have
been shown to increase A production via an effect on
-secretase cleavage of APP (10) whereas inhibition of cho-
lesterol synthesis has the opposite effect (11). The exact
process by which cholesterol can regulate A formation is
unknown, but there is increasing evidence to suggest that
cholesterol-rich regions of cell membranes, known as lipid
rafts, may play a part. Recent work has shown BACE to be
partially raft localized when expressed in Chinese hamster
ovary cells (19), and a small fraction of APP has also been
shown to be present in lipid rafts in both neurons in culture
(17) and mouse cerebral cortex (18).
In the present study, we provide evidence that A generation
in a neuronal cell line depends on lipid rafts. Riddell et al. (19)
have shown that depletion of cellular cholesterol in Chinese
hamster ovary cells causes BACE to dissociate from rafts, and
these conditions are also known to reduce A production (11).
Because only a small fraction of BACE is present in rafts under
normal conditions (18), we have taken a more direct approach
and have targeted BACE virtually exclusively to raft domains by
replacing the transmembrane and cytosolic domains of BACE
with a GPI-anchor attachment sequence. The production of both
A and sAPP was dramatically increased in cells expressing
GPI-BACE as compared with cells expressing WT-BACE. We
have also shown that disruption of the rafts by lovastatin and
MCD treatment caused GPI-BACE to dissociate from rafts
and that this treatment inhibited production of sAPP. This
result demonstrates that expression of GPI-BACE alone is not
sufficient to cause increased APP processing, and that the raft
localization of the enzyme is critical for the observed increase in
sAPP and A production. GPI anchor addition to BACE could
affect its intracellular distribution because the relative content of
raft microdomains may vary in different subcellular compart-
ments. However, the present results are also supported by the
observation that antibody cross-linking of APP and BACE
causes them to co-patch with known raft markers and also
increases A production (30).
As already stated, when we expressed GPI-BACE in an
SHSY5Y cell line, an increase in sAPP production was ob-
served with respect to the level seen in WT-BACE-expressing
cells. The main band of sAPP visible after SDSPAGE and
immunoblotting of media was increased 2-fold in GPI-BACE-
expressing cells. Interestingly, however, a second band at a
slightly lower molecular weight was increased 20-fold over the
low level seen from WT-BACE-expressing cells (Fig. 5C). This
band was no longer visible following cholesterol depletion. Both
bands could be shifted to lower molecular weights on removal of
O-glycans, suggesting that they are both mature forms of APP
(Fig. 6B).
APP is encoded by a single gene containing 18 exons. Alter-
native splicing of two of these exons results in multiple isoforms
being produced, the most predominant of which are APP695,
APP751, and APP770 (31–34). The two larger isoforms contain a
KPI domain whereas APP770 also contains an OX.2 domain.
APP695 lacks both these regions. When media from WT- or
GPI-BACE-expressing cells were immunoblotted with an anti-
body raised against the KPI domain of APP, only the larger band
of sAPP could be detected. It is likely, then, that the two
isoforms of sAPP produced by GPI-BACE-expressing cells
(Fig. 5C) derive from APP695 (lower band) and APP751770
(upper band).
These results imply that, under normal circumstances, when
wild-type BACE is present, most A produced is derived from
KPI-containing APP isoforms. This finding is consistent with a
previous report showing that, when individual APP isoforms are
expressed in cell lines, cells expressing the larger isoforms
produce more A than those expressing APP695 (35). When an
increased amount of BACE is present in raft domains, however,
both the KPI- and nonKPI-containing isoforms are cleaved. This
result could reflect a differential localization of the isoforms
within the membrane, allowing APP695 and BACE to come
together only when a large proportion of BACE is present in
rafts.
In summary, our results show that amyloidogenic processing
of APP by BACE in SHSY-5Y cells takes place far more
efficiently when BACE is raft-localized, suggesting that BACE
is the rate-limiting enzyme in this process, at least in this cell line.
Future transgenic studies using the GPI-BACE construct would
enable the pathological relevance of raft processing to be
explored further.
Changes in distribution of cholesterol and lipids within cell
membranes are known to occur during aging (36). It is possible,
therefore, that the local membrane environment may be altered
such that more BACE, andor other enzymes or cofactors
involved in amyloidogenic processing become raft-localized, and
therefore aging provides a more cooperative environment for
production of A. Strategies such as cholesterol reduction to
segregate BACE away from its substrate, APP, may therefore be
therapeutically viable. GPI-BACE itself may have potential use
in a screen for BACE inhibitors.
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